Hims & Hers Health said Wednesday it will offer five compounded peptide and longevity formulations as the first phase of its Peptides+ platform. None of the products are approved by the Food and Drug Administration. The company said they are authorized by law and made by pharmacies that are licensed and inspected by state boards of pharmacy.

The products include compounded sermorelin, glutathione and NAD+, plus vitamin B-12 and L-carnitine. The FDA has approved certain prescription forms of B-12 and L-carnitine for diagnosed deficiencies. Hims plans to add more U.S.-made peptides over time, including BPC-157 and TB-500. Most research on both has been done in animals, not humans.

Hims said more than 10,000 people signed up for its early access list within 15 days of its late October launch, a company spokesperson said.

Members will begin with an assessment of their health history and goals by a licensed provider trained in peptide therapies. Hims chief medical officer Dr. Anant Vinjamoori told CNBC that the company will check in with patients to see whether they are getting the results they want and will adjust doses or change compounds when needed. He said people with serious cardiovascular, liver or kidney disease will not be candidates for now.

Vinjamoori also acknowledged uncertainty. "We don't have all of this data that we're used to having with compounds like this," he said.

Outside experts raised concerns. Joshua Kritzer, a chemistry professor at Tufts University, said that without clinical testing, "all you have is anecdotal information." Paul Knoepfler, a cell biology and human anatomy professor at UC Davis Health, said dosing "really has not been established." He warned that injecting too much of a synthetic peptide could trigger immune responses.

Andrew Huberman, a neuroscientist and Stanford University School of Medicine professor who recently joined Hims' board, said in a statement that the compounds are "real medical treatments, not just a wellness trend."